Why is the Mesoblast share price crashing 9% today?

What is weighing on this high-flying stock on Tuesday? Let's find out.

| More on:
Shot of a young businesswoman looking stressed out while working in an office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price has returned from its trading halt and dropped into the red.

At the time of writing, the biotech company's shares are down 9% to $2.55.

Why is the Mesoblast share price sinking today?

The catalyst for today's weakness has been news that Mesoblast has successfully completed a major capital raising.

According to the release, the allogeneic cellular medicines developer for inflammatory diseases has completed a global private placement primarily to its existing major US, UK, and Australian shareholders.

This has seen the high-flying company raise a total of A$260 million (US$160 million) at a price of A$2.50 per new share. This represents a discount of 11% to where the Mesoblast share price last traded.

Unfortunately for retail shareholders, they have been excluded from this capital raising. The company has no plans to launch a share purchase plan (SPP) on this occasion.

Why is the company raising funds?

The release notes that proceeds from the capital raising will be used to fund a number of activities.

The first is the US commercial launch of Ryoncil (remestemcel-L) for steroid-refractory acute graft-versushost disease (SR-aGvHD) in pediatric patients. It was recently approved by the US Food and Drug Administration (FDA), which put a rocket under the Mesoblast share price.

So much so, the price that Mesoblast is raising funds is a premium of 47% to where its shares were trading a month prior to Friday's trading halt.

In addition, the company notes that the funds will be used to support clinical developments. This includes the acceleration of the second Phase 3 study in inflammatory chronic low back pain (CLBP) which is actively recruiting.

Funds will also be put towards the expansion of commercial manufacturing activities in preparation for product uptake and demand, as well as working capital and general corporate purposes.

Commenting on the capital raising, Mesoblast's chief executive, Dr. Silviu Itescu, said:

We appreciate the strong support from our shareholders as we scale-up production and provide to hospitals Ryoncil, the first and only FDA-approved mesenchymal stromal cell therapeutic, to treat children with life-threatening SR-aGvHD.

Huge turnaround

This capital raising marks an incredible turnaround in the fortunes of this biotech stock. A year ago, the Mesoblast share price was in the doldrums and fetching just 28 cents. This gave it a market capitalisation of approximately $300 million.

Fast forward to today and the company has almost raised as much as its market capitalisation from a year ago at a share price almost 10x greater than it was trading at then.

Should you invest $1,000 in Mesoblast Limited right now?

Before you buy Mesoblast Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man slumps crankily over his morning coffee as it pours with rain outside.
Earnings Results

This ASX healthcare stock is crashing 30% on half year results

Why is this stock crashing deep into the red today? Let's find out.

Read more »

Buy, hold and sell ratings written on signs on a wooden pole.
Healthcare Shares

CSL shares: Buy, sell or hold in 2025?

Three investment experts offer their view on the outlook for CSL shares.

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Earnings Results

Why has this ASX 200 healthcare stock crashed 24% in 2 days?

It has been a tough start to the week for this medical device company's shareholders.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

This little-known healthcare company is now the 17th-largest business in the ASX 200

This stock isn’t well-known, but it’s a market leader with significant potential.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why I think this ASX small-cap share is a buy at $1.18

After falling almost 17% over the past year, I see a lot of value at the current price.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Healthcare Shares

Up 175% in 12 months: Bell Potter just upgraded this high-flying ASX 200 share

This share has smashed the market in recent times but the gains may not be over.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 25% on big UK news

Investors are sending this ASX healthcare stock rocketing on Friday. But why?

Read more »

two men shake hands on a deal.
Healthcare Shares

Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news

This share is rocketing on Friday after accepting a takeover offer.

Read more »